What the business is, and whether it's a good one at a fair price.
Sells branded pharmaceutical formulations in India across ten therapy areas, with cardiac, oral anti-diabetics (OAD), biologics and insulins among the largest contributors. The domestic branded formulations (DBF) business grew 14% year-on-year in Q1 FY27 to Rs 801 cr, with seven of ten therapies delivering double-digit growth. A biologics and insulin manufacturing facility at Bhopal is scheduled to commercialise in August 2026, intended to support future insulin aspart and other analogue launches. A semaglutide brand (Sanghi) launched in Q1 FY27 captured 20% volume share and 14% value share in its launch quarter, while an earlier GLP-1 brand (Sundae) ranks #1 in prescriptions with about 21% share. The company also runs a Swiss parenteral operation under EU GMP remediation and an export franchise, both smaller contributors. Consolidated Q1 FY27 revenue was Rs 873 cr at a 34% EBITDA margin; FY26 full-year revenue was Rs 3,129 cr at a 35.5% EBITDA margin.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from ERIS LIFESCIENCES LIMITED's filed financials and exchange disclosures
ERIS LIFESCIENCES LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ERIS.
Yes. Over the trailing twelve months ERIS LIFESCIENCES LIMITED reported a net profit of ₹666 Cr on revenue of ₹3,230 Cr.
Not in the latest reported year — ERIS LIFESCIENCES LIMITED's dividend payout for FY26 was nil.
No. Debt stands at 0.59× equity, and it carries net debt of ₹2,255 Cr. That is lower than 14% of its 171 Pharmaceuticals peers.
On trailing P/E, ERIS LIFESCIENCES LIMITED ranks 84 of 169 in Pharmaceuticals — cheaper than 51% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session ERIS LIFESCIENCES LIMITED moves 0.88% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by ERIS LIFESCIENCES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
